FLT3/TrKA-IN-1

FLT3/TrKA-IN-1

• UNSPSC Description: FLT3/TrKA-IN-1 is a potent FLT3/TrKA dual kinase inhibitor with the IC50s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML)[1].
• Target Antigen: Apoptosis; FLT3; Trk Receptor
• Type: Reference compound
• Related Pathways: Apoptosis;Neuronal Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/flt3-trka-in-1.html
• Solubility: 10 mM in DMSO
• Smiles: CC(NC1=CC=C(C=C1)N2C=NC3=CC(C4=CC=C(C=C4)OCCN5CCCCC5)=CC=C32)=O
• Molecular Weight: 454.56
• References & Citations: [1]Dokla EME, et al. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Bioorg Med Chem. 2022; 56:116596.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported